title: Pharmacotherapy for the prevention of post-ERCP pancreatitis.
abstract: Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.
authors.forename: Erina
authors.initials: E
authors.lastname: Foster
authors.forename: Joseph
authors.initials: J
authors.lastname: Leung
mesh_terms: D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D010195:Pancreatitis / Q000209:etiology* / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
chemical_list: D005765:Gastrointestinal Agents; D015282:Octreotide